These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1118 related articles for article (PubMed ID: 25908243)

  • 1. Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the association for molecular pathology.
    Gold B; Cankovic M; Furtado LV; Meier F; Gocke CD
    J Mol Diagn; 2015 May; 17(3):209-24. PubMed ID: 25908243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The feasibility of using mutation detection in ctDNA to assess tumor dynamics.
    Yi X; Ma J; Guan Y; Chen R; Yang L; Xia X
    Int J Cancer; 2017 Jun; 140(12):2642-2647. PubMed ID: 28124376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liquid biopsy: will it be the 'magic tool' for monitoring response of solid tumors to anticancer therapies?
    Gingras I; Salgado R; Ignatiadis M
    Curr Opin Oncol; 2015 Nov; 27(6):560-7. PubMed ID: 26335664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility.
    Ignatiadis M; Lee M; Jeffrey SS
    Clin Cancer Res; 2015 Nov; 21(21):4786-800. PubMed ID: 26527805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Classifying circulating tumor cells to monitor cancer progression.
    Economopoulou P; Georgoulias V; Kotsakis A
    Expert Rev Mol Diagn; 2017 Feb; 17(2):153-165. PubMed ID: 28032524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy.
    Alix-Panabières C; Pantel K
    Cancer Discov; 2016 May; 6(5):479-91. PubMed ID: 26969689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanotechnology Strategies for the Analysis of Circulating Tumor DNA: A Review.
    Chen X; Wang L; Lou J
    Med Sci Monit; 2020 Mar; 26():e921040. PubMed ID: 32200389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A headlight on liquid biopsies: a challenging tool for breast cancer management.
    Massihnia D; Perez A; Bazan V; Bronte G; Castiglia M; Fanale D; Barraco N; Cangemi A; Di Piazza F; Calò V; Rizzo S; Cicero G; Pantuso G; Russo A
    Tumour Biol; 2016 Apr; 37(4):4263-73. PubMed ID: 26790442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liquid biopsy and PCR-free ultrasensitive detection systems in oncology (Review).
    Finotti A; Allegretti M; Gasparello J; Giacomini P; Spandidos DA; Spoto G; Gambari R
    Int J Oncol; 2018 Oct; 53(4):1395-1434. PubMed ID: 30085333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating Biomarkers for Prediction of Treatment Response.
    Cappelletti V; Appierto V; Tiberio P; Fina E; Callari M; Daidone MG
    J Natl Cancer Inst Monogr; 2015 May; 2015(51):60-3. PubMed ID: 26063889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.
    Punnoose EA; Atwal S; Liu W; Raja R; Fine BM; Hughes BG; Hicks RJ; Hampton GM; Amler LC; Pirzkall A; Lackner MR
    Clin Cancer Res; 2012 Apr; 18(8):2391-401. PubMed ID: 22492982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine.
    Batth IS; Mitra A; Manier S; Ghobrial IM; Menter D; Kopetz S; Li S
    Ann Oncol; 2017 Mar; 28(3):468-477. PubMed ID: 27998963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liquid Biopsy beyond Circulating Tumor Cells and Cell-Free DNA.
    Junqueira-Neto S; Batista IA; Costa JL; Melo SA
    Acta Cytol; 2019; 63(6):479-488. PubMed ID: 30783027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating tumor cells and circulating tumor DNA: What surgical oncologists need to know?
    Cabel L; Proudhon C; Mariani P; Tzanis D; Beinse G; Bieche I; Pierga JY; Bidard FC
    Eur J Surg Oncol; 2017 May; 43(5):949-962. PubMed ID: 28185687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic technologies for circulating tumour cells and exosomes.
    Shao H; Chung J; Issadore D
    Biosci Rep; 2015 Nov; 36(1):e00292. PubMed ID: 26604322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in Circulating Tumor DNA Analysis.
    Perakis S; Auer M; Belic J; Heitzer E
    Adv Clin Chem; 2017; 80():73-153. PubMed ID: 28431643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential of circulating biomarkers in liquid biopsy diagnostics.
    Yeo JC; Lim CT
    Biotechniques; 2018 Oct; 65(4):187-189. PubMed ID: 30284936
    [No Abstract]   [Full Text] [Related]  

  • 18. Circulating nucleic acids as a tumor marker.
    Chan KC; Lo YM
    Histol Histopathol; 2002; 17(3):937-43. PubMed ID: 12168805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell-free circulating tumor DNA in cancer.
    Qin Z; Ljubimov VA; Zhou C; Tong Y; Liang J
    Chin J Cancer; 2016 Apr; 35():36. PubMed ID: 27056366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating tumor DNA as a liquid biopsy target for detection of pancreatic cancer.
    Takai E; Yachida S
    World J Gastroenterol; 2016 Oct; 22(38):8480-8488. PubMed ID: 27784960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.